FEHBlog

TGIF

According to this Wall Street Journal report, the Administration announced this week that the Treasury Department is expected to reach the bottom of its bag of tricks on November 5.  Congress needs to raise the debt limit by that date. Consequently, we have now have two panic dates — November 5 and December 11, which is the date that the current continuing resolution expires. Congress will be back in session next week. Here is a link to The Week in Congress report on this week’s activities on Capitol Hill.

The Wall Street Journal also reports today that momentum is building to repeal the 40% excise tax on high cost, employer sponsored health coverage. In a pleasant surprise, the Hill reports that Congress has passed, and the President will sign, an amendment to the ACA that will limit the small group health insurance pricing rules to groups with no more than 50 employees. Absent that this agreement, the ACA would have boosted the upper threshold to 100 employees. This is a big savings for employers in the 51 to 100 employee group. So there is hope that this crazy excise tax will be repealed.

Following up on yesterday’s post, take a look at this Healthcare Dive article on the disruption that the ICD-10 is likely to cause over time.

Finally and because the FEHBlog is not a Luddite, the FEHBlog was impressed that Walgreens, according to Medcity News, is partnering with MDLive to add a telemedicine feature to its popular app.

Happy New Federal Fiscal Year!

Today is the beginning of the new federal fiscal year 2016. Today also marks the implementation of both the ICD-10 coding set for electronic health plan claims and the latest Medicare reimbursement scheme for hospitals and other facilities.

Modern Healthcare reports all quiet on the ICD-10 front. The FEHBlog expects the crash to occur in a few weeks, but he would be happy if it didn’t. He does not expect any sizable bang for the buck from this sea change.

Also here’s a heads up to the FEHBlog’s readers who are FEHB Program enrollees. OPM is readying a family member eligibility audit for launch. HMS Employer Solutions will be conducting the audit on OPM’s behalf. Here are links to a recent benefit administration letter and Fast Facts on the new program.

Rate charts

Yesterday I received comments that the link on opm.gov to the 2016 fee for service plan / non-postal rate chart was broken so the FEHBlog’s own link to the chart.  The FEHBlog just received similar comments about the other rate charges so here they are

Last year there was a big problem with the Postal rates posted on these charts. The FEHBlog has confirmed with his Postal Service union amigos that the published 2016 Postal rates are accurate.  

The Union is Preserved

The Washington Post reports that both Houses of Congress have approved a continuing resolution funding the federal government through December 11, 2015.

If you are an FEHB Program enrollee, check your plan’s website for information about 2016 benefit changes. Blue Cross FEP was first out of the box on that front.

The premium announcement

Here are links to the Washington Post, Federal Times, Govexec, and Business Insurance reports  on the OPM announcement of 2016 FEHBP premiums made early this afternoon.

The FEHBlog has received a few comments from readers who are dismayed over the fact that the enrollee contribution for the new self plus one coverage is more than the enrollee contribution for self plus family coverage in certain plans. There is no such thing as a good surprise. The Washington Post advises that

[E]nrollees should check premiums carefully before electing self plus one, officials said. While the total premium costs are capped at the amount for family enrollments, because of the way the premium sharing formula works, in about 5 percent of plans the enrollee share for a self plus one enrollment will be higher than that for a family enrollment.  

The Business Insurance article notes that

Escalating prescription drug costs, as has been the case for many private-sector employers, are a key factor in the sharp rise in premiums.  “One contributing factor to the somewhat higher FEHB premium increase than in the past several years is an uptick in the growth of drug costs. Drug costs are a much larger factor for the FEHB compared to most other employer-sponsored programs because annuitants, for whom drugs are the majority of benefits, are included in the FEHB risk pool. Drugs represent 26.5% of program costs versus 10% for a typical employer,” OPM said in a statement.

FEHBlog readers should know that rising drug costs are a real problem for all health plans inside and outside the FEHBP. The major actuarial consulting firm Milliman reports that “Prescription drug costs spiked significantly, growing by 13.6% from 2014 to 2015.” However, pooling employees and annuitant medical costs together is a saving grace of the FEHBP.  The FEHBP’s percentage of drug benefit costs in relation to total costs would be in line with other employer plans if it weren’t for the fact that Medicare pays the bulk of hospital costs for Medicare eligible FEHBP annuitants.

Non-postal FFS plan rates

OPM’s website must be hiccoughing as the FEHBlog is getting comments from clients and readers that the fee for service plan non-postal rates link does not work on OPM.gov. The FEHBlog was able to download that chart. Here is a better link.

Weekend update

The month of October starts this week. That means

  • A new federal fiscal year starts Thursday.  Congress is working on a continuing resolution to fund the federal government past Wednesday.  Here is a link to the Week in Congress’s report on last week’s activities on the Hill. 
  • The ICD-10 coding set compliance date also is October 1.  Government Health IT reports that according to GAO the implementation outcome is impossible to predict.  This is a big change for providers and payers. The FEHBlog expects that it will be a mess at least over the next six months despite best efforts.   
  • The U.S. Supreme Court returns to work this week. It’s first session of the new term will be a week from tomorrow. 
  • The 2016 FEHBP rates likely will be released this week. 
Late last week, The Segal Company, a large benefit consulting firm, issued its 19th annual survey on health care costs for the coming year 2016.  Segal’s key findings are as follows:
  • Trend rates for health maintenance organizations (HMOs) and open-access preferred provider organization (PPO)/point-of-service (POS) plans — the two most common medical plan types offered — are projected to differ by 1 percentage point: 6.8 percent for HMOs and 7.8 percent for PPO/POS plans.
  • Trend rates for prescription drug coverage are expected to be significantly higher in 2016: 11.3 percent for carve-out coverage for actives and retirees under age 65 and 10.9 percent for retirees age 65 and over. Both projections are roughly 3 percentage points greater than projections for 2015.
  • The projected specialty drug/biotech drug cost trend rate is expected to remain extremely high at 18.9 percent, but slightly lower than the projection for 2015.
  • Price inflation for prescription drugs and hospital stays are the overwhelming driver of cost increases, especially for prescription drugs, where trend is approaching double digits (9.8 percent), well above the current Consumer Price Index for all goods and services (0.1 percent).
Speaking of prescription drug price trends, get a load of this article on Kaiser Health News — 

Many doctors are choosing a better-safe-than-sorry approach to heading off heart trouble in very elderly patients. Inexpensive statin drugs are given to millions of people to reduce cholesterol, even many who do not show signs of heart disease. But a recent study has found that seniors with no history of heart trouble are now nearly four times more likely – from 9 percent to 34 percent – to get those drugs than they were in 1999.
Here’s the catch: For patients of that age, there is little research showing statins’ preventive heart benefits outweigh possible risks, which can include muscle pain and the onset of diabetes.  * * * With the average life expectancy at 76 for men and 81 for women in the U.S., drug companies haven’t funded such studies in people above 79. 

Also, the FEHBlog noticed this  thought-provoking article about electronic data encryption on the Federal News Radio site. The point of the article is that “data encryption should be done in such a way as to make it separate from the operating system or the application doing the encryption.”

HHS’s Office for Civil Rights has posted a lengthy FAQ on its even lengthier proposed rule on Public Health Service Act Section 1557, an ACA provision prohibiting various forms discrimination against individuals receiving services or coverage under federally funded programs such as the FEHBP.  The proposed rule applies only to HHS funded programs such as qualified health plans, Medicare, and Medicaid.

Enjoy the super moon eclipse / blood Moon tonight. 

TGIF

The FEHBlog expected that there would be no government shutdown on October 1, and mark the tape the Washington Post reports today follow the Speaker of the House John Boehner’s unexpected resignation,  “House Republicans said there was agreement to pass a clean spending bill to avert a government shutdown.” Presumably this decision is aligned with the Senate Republican leadership’s plan to vote for a continuing resolution that would expire on December 11 as reported by Federal News Radio.  House Majority Leader Kevin McCarthy (R Calif) is expect to be the new Speaker on November 1.

The Wall Street Journal reminded the FEHBlog that there finally is a biosimilar drug on sale in the U.S. — Zarxio which can be used in place of Amgen’s blockbuster Neupogen anti-infection drug for cancer patients. Zarxio has been sold in Europe since 2009 but this is the first year that Zarxio has outsold Neupogen across the pond. The Journal strikes a hope chord:

[T]here is reason to believe that the uptake of biosimilars could follow a smoother trajectory in the U.S. Kate Keeping, senior director of biosimilars research at Decision Resource Group, a health-care research firm, said U.S. physicians she had surveyed were more familiar with biosimilars than European physicians were before biosimilars were launched there. “It’s less likely that you’re going to see restrictions on uptake due to physicians being hesitant,” she said.

OPM did not announced the FEHBP 2016 premiums this week (as of 12:40 pm).  The FEHBlog can’t remember when the new rates were announced in October but here are a few days left in September.